Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
|Articles|June 30, 2015
Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers
Author(s)Sue Friedman
Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.
Advertisement
Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses
Advertisement
Related to this article
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Pancreatic Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
3
The Breast Cancer Test Many Patients Don’t Know to Ask For
4
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
5